This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

BAROSTIM NEO HTN Pivotal Trial

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
CVRx, Inc.
ClinicalTrials.gov Identifier:
NCT01679132
First received: August 31, 2012
Last updated: January 18, 2017
Last verified: January 2017
August 31, 2012
January 18, 2017
January 2013
September 2017   (Final data collection date for primary outcome measure)
  • Primary Safety Objective [ Time Frame: 30 days ]
    To demonstrate the safety of the Neo system by reporting all adverse events that are complications between implant and 30 days post-implant in the device arm. The incidence of adverse events will be categorized by relatedness.
  • Primary Efficacy Objective [ Time Frame: 6 months ]
    To demonstrate a significant reduction between the two treatment arms of protocol defined automated office cuff systolic blood pressure (SBP) from baseline to 6 months post-activation.
  • To demonstrate the safety of the Neo system by evaluating the Type 1 system and procedure related complication free rate through 30 days post-procedure. [ Time Frame: 30 days ]
  • To demonstrate a significant reduction of BpTRU systolic blood pressure (SBP) at 3 months post activation. [ Time Frame: 3 months ]
Complete list of historical versions of study NCT01679132 on ClinicalTrials.gov Archive Site
  • Secondary Efficacy Objective 1 [ Time Frame: 12 months ]
    To demonstrate a significant reduction within the device arm of office cuff systolic blood pressure (SBP) between baseline and 12 months post-activation.
  • Secondary Efficacy Objective 2 [ Time Frame: 12 months ]
    To demonstrate a significant reduction within the device arm of 24-hour ambulatory systolic blood pressure (SBP) between baseline and 12 months post-activation.
  • Secondary Safety Objective [ Time Frame: 6 months ]
    To demonstrate the safety of the Neo system by reporting all hypertensive emergencies from activation to 6 months post activation. The incidence of hypertensive emergencies will be categorized by study arm.
  • To demonstrate a significant reduction of BpTRU systolic blood pressure (SBP) at 6 months post activation. [ Time Frame: 6 months ]
  • To demonstrate a significant reduction of 24-hour ambulatory systolic blood pressure (SBP) at 6 months post-activation. [ Time Frame: 6 months ]
Not Provided
Not Provided
 
BAROSTIM NEO HTN Pivotal Trial
CVRx BAROSTIM NEO Hypertension Pivotal Trial

The BAROSTIM NEO HTN trial is a prospective, randomized, controlled trial to demonstrate the safety and efficacy of the Barostim Neo system in subjects with resistant hypertension.

Currently, the BAROSTIM NEO HTN trial is not actively enrolling. CVRx is conducting long-term follow-up of patients implanted with the BAROSTIM NEO device. This update was not done for any subject protection concerns that would preclude continuation of the investigation.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Masking Description:
Open Label
Primary Purpose: Treatment
Uncontrolled Hypertension
  • Device: Neo Baroreflex Activation Therapy System
    Other Names:
    • Neo System
    • Barostim Neo System
  • Other: Standard of care medical management only
    Patients will continue with medical therapy for standard of care of their hypertension.
  • Experimental: Neo Baroreflex Activation Therapy System
    Patients are randomized to receive Neo Baroreflex Activation Therapy System device plus optimal medical management.
    Intervention: Device: Neo Baroreflex Activation Therapy System
  • Active Comparator: Medical Management Arm
    Patients are randomized to receive optimal medical management alone.
    Intervention: Other: Standard of care medical management only
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
310
September 2017
September 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria Highlights:

  • Age at least 21 years and no more than 80 years at the time of randomization.
  • On four or more maximally tolerated anti-hypertensive medications, one of which is a diuretic. The antihypertensive medication regimen must remain unchanged for 4 weeks prior to screening and must be expected to remain unchanged for at least 6 months during follow-up.
  • Protocol defined systolic blood pressure greater than or equal to 160 mmHg.
  • Protocol defined 24-hour Ambulatory Blood Pressure Monitoring (ABPM) greater than or equal to 135 mmHg.
  • Serum estimated glomerular filtration rate (eGFR) > 29 mL/min/1.73 m^2.
  • Appropriate surgical candidate.
  • Women of childbearing potential must use a medically accepted method of birth control and agree to continue use of this method for the duration of the study. Women of childbearing potential must have a negative pregnancy test within 14 days prior to randomization.

Exclusion Criteria Highlights:

  • Known or suspected baroreflex failure or autonomic neuropathy.
  • Myocardial infarction, hypertensive crisis, symptomatic orthostatic hypotension, unstable angina, syncope, or cerebral vascular accident within the 3 months.
  • Hypertension secondary to an identifiable and treatable cause other than sleep apnea.
  • Prior surgery, radiation, or endovascular stent placement in the carotid sinus region.
Sexes Eligible for Study: All
21 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01679132
360039
Yes
Not Provided
Not Provided
CVRx, Inc.
CVRx, Inc.
Not Provided
Study Chair: George Bakris, MD The University of Chicago Medicine
Study Chair: John Bisognano, MD University of Rochester
Study Chair: Fred Weaver, MD Keck School of Medicine of the University of Southern California
Study Chair: William Abraham, MD Ohio State University
CVRx, Inc.
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP